JP2008518007A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518007A5 JP2008518007A5 JP2007538989A JP2007538989A JP2008518007A5 JP 2008518007 A5 JP2008518007 A5 JP 2008518007A5 JP 2007538989 A JP2007538989 A JP 2007538989A JP 2007538989 A JP2007538989 A JP 2007538989A JP 2008518007 A5 JP2008518007 A5 JP 2008518007A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- formulation according
- capreomycin
- aggregate
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 27
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 claims 6
- 108010065839 Capreomycin Proteins 0.000 claims 6
- 229960004602 capreomycin Drugs 0.000 claims 6
- 239000000843 powder Substances 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 206010057190 Respiratory tract infections Diseases 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- -1 rifapicin Chemical compound 0.000 claims 3
- 201000008827 tuberculosis Diseases 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 229960003376 levofloxacin Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 1
- AHJGUEMIZPMAMR-WZTVWXICSA-N 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=C(F)C(N)=NC(N2C3=C(Cl)C(N4CC(O)C4)=C(F)C=C3C(=O)C(C(O)=O)=C2)=C1F AHJGUEMIZPMAMR-WZTVWXICSA-N 0.000 claims 1
- LEILBPMISZFZQK-GFCCVEGCSA-N 5-amino-7-[(7s)-7-azaniumyl-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylate Chemical compound C12([C@H](N)CN(C1)C1=C(C3=C(C(C(C(O)=O)=CN3C3CC3)=O)C(N)=C1F)C)CC2 LEILBPMISZFZQK-GFCCVEGCSA-N 0.000 claims 1
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 206010027249 Meningitis meningococcal Diseases 0.000 claims 1
- 201000010924 Meningococcal meningitis Diseases 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000012867 bioactive agent Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 229950006412 delafloxacin Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229960003923 gatifloxacin Drugs 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 claims 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 1
- 229960003752 oseltamivir Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002599 rifapentine Drugs 0.000 claims 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 claims 1
- 229960000888 rimantadine Drugs 0.000 claims 1
- 229960003177 sitafloxacin Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62373804P | 2004-10-29 | 2004-10-29 | |
| PCT/US2005/037484 WO2007011396A2 (en) | 2004-10-29 | 2005-10-19 | Particles for treatment of pulmonary infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008518007A JP2008518007A (ja) | 2008-05-29 |
| JP2008518007A5 true JP2008518007A5 (enExample) | 2008-12-04 |
Family
ID=37667331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538989A Pending JP2008518007A (ja) | 2004-10-29 | 2005-10-19 | 肺感染症の処置のための粒子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8846607B2 (enExample) |
| EP (1) | EP1809252A2 (enExample) |
| JP (1) | JP2008518007A (enExample) |
| CN (1) | CN101090711A (enExample) |
| AU (1) | AU2005334514B2 (enExample) |
| BR (1) | BRPI0517374A (enExample) |
| CA (1) | CA2585859C (enExample) |
| IL (1) | IL182785A0 (enExample) |
| RU (1) | RU2007119721A (enExample) |
| WO (1) | WO2007011396A2 (enExample) |
| ZA (1) | ZA200703452B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
| PL3067064T3 (pl) | 2008-12-09 | 2020-11-02 | Novavax, Inc. | Zmodyfikowane białka f rsv i sposoby ich wykorzystania |
| RU2399385C1 (ru) * | 2009-03-10 | 2010-09-20 | Общество с ограниченной ответственностью "Научно-производственная фирма "НОРД" | Способ профилактической обработки животных и птиц |
| JP2012524817A (ja) * | 2009-04-24 | 2012-10-18 | シェーリング コーポレイション | 標的粒子サイズを有する、活性医薬を含む凝集体配合物 |
| CN105832678A (zh) | 2009-05-27 | 2016-08-10 | 株式会社三养生物制药 | 生物利用度提高的包含难溶性药物的微球及其制备方法 |
| CN102573886A (zh) * | 2009-09-17 | 2012-07-11 | 相互制药公司 | 用抗病毒剂治疗哮喘的方法 |
| CN102225058A (zh) * | 2011-06-22 | 2011-10-26 | 中国药科大学 | 磷酸奥司他韦吸入粉雾剂及其制备方法 |
| ES2814336T3 (es) | 2012-04-13 | 2021-03-26 | Glaxosmithkline Ip Dev Ltd | Partículas de agregado |
| RU2562550C2 (ru) * | 2013-12-19 | 2015-09-10 | Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных" (ФГБНУ ВНИИБТЖ) | Способ специфической профилактики туберкулеза |
| US10426829B2 (en) * | 2015-09-03 | 2019-10-01 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
| WO2018226949A1 (en) | 2017-06-08 | 2018-12-13 | Pai Life Sciences Inc. | Cpzen compositions and uses |
| CN109260180A (zh) * | 2017-07-17 | 2019-01-25 | 北京盈科瑞创新药物研究有限公司 | 一种盐酸莫西沙星雾化吸入用溶液制剂及其制备方法 |
| ES3028362T3 (en) | 2017-07-24 | 2025-06-19 | Novavax Inc | Methods and compositions for treating respiratory disease |
| CA3092984A1 (en) | 2018-03-19 | 2019-09-26 | Novavax, Inc. | Multivalent influenza nanoparticle vaccines |
| MX2021000796A (es) * | 2018-07-24 | 2021-06-15 | Univ Texas | Composiciones de partículas terapéuticamente activas con superficie modificada por congelación ultra-rápida. |
| IL297852A (en) * | 2020-05-01 | 2023-01-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | E protein channel blockers, and orf3 inhibitors, against covid 19 |
| AU2021270426A1 (en) * | 2020-05-14 | 2022-12-08 | Kowa Company, Ltd. | Novel inhalant |
| US20250268857A1 (en) * | 2020-08-28 | 2025-08-28 | Shigadry With Earth Co., Ltd. | Method and device for infection prevention |
| EP4271679A4 (en) * | 2021-02-01 | 2024-09-11 | The Global Alliance for TB Drug Development, Inc. | AMORPHOUS FORM OF PRETOMANIDES |
| JP2024049405A (ja) * | 2021-02-22 | 2024-04-10 | 興和株式会社 | 新規吸入剤 |
| CN113907360A (zh) * | 2021-07-30 | 2022-01-11 | 湖南达侑科技有限公司 | 植物甾醇磷脂组合物及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| IS1796B (is) | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
| JP2930421B2 (ja) | 1994-02-28 | 1999-08-03 | メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤組成物、その製造方法及びその使用方法 |
| ATE264096T1 (de) | 1994-03-07 | 2004-04-15 | Nektar Therapeutics | Verfahren und mittel zur verabreichung von insulin über die lunge |
| US5814617A (en) | 1994-10-07 | 1998-09-29 | The United States Of America As Represented By The Secretary Of The Navy | Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene |
| DK0752245T3 (da) | 1995-07-05 | 2002-09-09 | Europ Economic Community | Biokompatible og bionedbrydelige nanopartikler udviklet til absorption og afgivelse af proteinholdige lægemidler |
| US6143211A (en) | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US20020052310A1 (en) | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
| US6517860B1 (en) * | 1996-12-31 | 2003-02-11 | Quadrant Holdings Cambridge, Ltd. | Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery |
| US20030059471A1 (en) * | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
| US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| US6586008B1 (en) | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| CN1188111C (zh) | 1999-10-29 | 2005-02-09 | 耐科塔医药公司 | 分散性得到改进的干粉组合物 |
| US6766799B2 (en) | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
| EP1458361A4 (en) * | 2001-11-20 | 2007-04-25 | Advanced Inhalation Res Inc | COMPOSITIONS FOR DISTRIBUTING PRODUCTS WITH LASTING EFFECT |
| GB0216562D0 (en) | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
| WO2004024213A2 (en) * | 2002-09-12 | 2004-03-25 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Aerosolized capreomycin for inhibition of pulmonary tuberculosis |
| CN1694689A (zh) | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 |
| ATE482706T1 (de) | 2003-02-10 | 2010-10-15 | Bayer Schering Pharma Ag | Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen |
-
2005
- 2005-10-19 US US11/720,595 patent/US8846607B2/en not_active Expired - Fee Related
- 2005-10-19 JP JP2007538989A patent/JP2008518007A/ja active Pending
- 2005-10-19 BR BRPI0517374-4A patent/BRPI0517374A/pt not_active IP Right Cessation
- 2005-10-19 CN CNA2005800449753A patent/CN101090711A/zh active Pending
- 2005-10-19 EP EP05858453A patent/EP1809252A2/en not_active Withdrawn
- 2005-10-19 WO PCT/US2005/037484 patent/WO2007011396A2/en not_active Ceased
- 2005-10-19 AU AU2005334514A patent/AU2005334514B2/en not_active Ceased
- 2005-10-19 CA CA2585859A patent/CA2585859C/en not_active Expired - Fee Related
- 2005-10-19 RU RU2007119721/15A patent/RU2007119721A/ru not_active Application Discontinuation
-
2007
- 2007-04-25 IL IL182785A patent/IL182785A0/en unknown
- 2007-04-26 ZA ZA200703452A patent/ZA200703452B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008518007A5 (enExample) | ||
| RU2007119721A (ru) | Частицы для лечения легочной инфекции | |
| JP7623854B2 (ja) | 乾燥粉末配合および使用方法 | |
| Yu et al. | Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation | |
| Sabuj et al. | Inhaled antibiotic-loaded polymeric nanoparticles for the management of lower respiratory tract infections | |
| JP2012503668A5 (enExample) | ||
| CN106456595A (zh) | 用于系统性病症的肥大细胞稳定剂治疗 | |
| JP2011520911A5 (enExample) | ||
| JP2013536845A5 (enExample) | ||
| WO2017027387A1 (en) | Methods for the treatment of mast cell related disorders with mast cell stabilizers | |
| JP2015515968A5 (enExample) | ||
| CN115768402A (zh) | 用于治疗急性肺损伤的5-氨基-2,3-二氢-1,4-酞嗪二酮 | |
| JP2007520507A5 (enExample) | ||
| JP2016535094A5 (enExample) | ||
| TW200815003A (en) | Treating cystic fibrosis with antibiotics via a swirler delivery | |
| Kaur | Pulmonary drug delivery system: Newer patents | |
| WO2015027848A1 (zh) | 含有帕拉米韦和/或其衍生物制剂的给药方法 | |
| Chaudhary et al. | Recent updates in inhalable drug delivery system against various pulmonary diseases: challenges and future perspectives | |
| JP2023521898A (ja) | カテキン含有組成物及び使用 | |
| Wang et al. | Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles | |
| Debnath et al. | Status of inhalable antimicrobial agents for lung infection: progress and prospects | |
| CN116963738A (zh) | 用于SARS-CoV-2感染的后遗症的预防和治疗的鲁米诺 | |
| Pardeshi et al. | Strategies for enhanced drug targeting to inflamed lungs: novel perspectives | |
| Tamboli et al. | Exploring the Frontier of Inhalation Therapy: A Review of Dry Powder Inhalers for Precision Management of Inflammatory Lung Diseases | |
| WO2023141278A3 (en) | Composite particle formulations and applications thereof |